Physician profile

Roger A Sacry

Family Medicine · Carthage, MO

NPI 1528009529

$1,068.49

in general payments reported to CMS, 2019-2025

18 companies · $13.49 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$112.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $143.19 2019-2020
Janssen Pharmaceuticals, INC $122.63 2019
Boehringer Ingelheim Pharmaceuticals, INC. $121.03 2019-2020
Abbvie INC. $112.46 2023-2025
Amgen INC. $83.00 2019-2020
Allergan, INC. $65.42 2019-2020
Otsuka America Pharmaceutical, INC. $56.79 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $55.56 2019
Astrazeneca Pharmaceuticals Lp $52.69 2019-2020
Novartis Pharmaceuticals Corporation $46.64 2019
Merck Sharp & Dohme LLC $45.11 2019
Lilly USA, LLC $39.57 2019
Pfizer INC. $36.64 2019-2020
Sanofi-Aventis U.S. LLC $22.86 2019
Glaxosmithkline, LLC. $22.30 2019
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $19.47 2019
Sanofi Pasteur INC. $12.17 2019
Teva Pharmaceuticals USA, INC. $10.96 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roger A Sacry

$1,068.49

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC

https://glasscript.com/doctor/23621/roger-a-sacry

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.